Treatment options for retinal diseases, such as neovascular age-related macular
degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded …

The major challenge faced by today's pharmacologist and formulation scientist is ocular
drug delivery. Topical eye drop is the most convenient and patient compliant route of drug …

Ocular drug delivery has been a major challenge for clinical pharmacologists and
biomaterial scientists due to intricate and unique anatomical and physiological barriers in …

The impact of proteins and peptides on the treatment of various conditions including ocular
diseases over the past few decades has been advanced by substantial breakthroughs in …

Ocular drug delivery has seen several advances in the past few decades, with respect to
new drugs, improved formulations, targeted delivery, as well as exploration of new routes of …

Nanocarriers have been explored for delivering drugs and other bioactive molecules for well
over 35 years. Since the introduction of Doxil®, a nanoliposomal delivery system for the …

Presently, different types of eye diseases, such as glaucoma, myopia, infection, and dry eyes
are treated with topical eye drops. However, due to ocular surface barriers, eye drops …

Currently, the treatment for ocular neovascular diseases, including diabetic macular edema
(DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal …

Intravitreal administration of drugs has raised a large interest during the last two decades
improving the treatment of infectious diseases of the posterior segment of the eye or …

Liposomal formulations were significantly explored over the last decade for the ophthalmic
drug delivery applications. These formulations are mainly composed of phosphatidylcholine …